Specialised Committee on Clinical Diagnosis and Treatment Guidelines of the Interventionalists Branch of the Chinese Physicians Association (2021) Clinical Practice Guidelines for Transarterial Chemoembolisation (TACE) Treatment of Hepatocellular Carcinoma in China (2021 Edition). Chinese Medical Journal, 101, 1848-1862.

has been cited by the following article:

• TITLE: Advances in Conversion Therapy for Primary Unresectable Hepatocellular Carcinoma

  AUTHORS: Xinhua Wu, Zhengrong Shi

  KEYWORDS: Hepatocellular Carcinoma, Transarterial Chemoembolization (TACE), Hepatic artery Infusion Chemotherapy (HAIC), Targeted Therapy, Immunotherapy

  JOURNAL NAME: Journal of Cancer Therapy, Vol.15 No.4, April 17, 2024

  ABSTRACT: Primary liver cancer is one of the most common malignant tumours in the world, and according to statistics, about half of liver cancers occur in China, which seriously threatens the lives and health of people around the world, especially in China. Hepatocellular carcinoma is the most common type, accounting for about 90 per cent of primary liver cancers. Most patients are asymptomatic in the early stage and fail to pay attention to it. Most of the patients are in the middle or late stage when they are first diagnosed, and only 20% - 30% of them can receive radical hepatectomy. Patients are through the treatment to make the tumour shrinkage and downstaging, to achieve the condition of resectable, that is, the conversion treatment. Conversion therapy has great potential for development and has now become an indispensable treatment for intermediate and advanced hepatocellular carcinoma. However, there are various treatment options for conversion therapy, no uniform guidelines to guide clinical selection, and the overall conversion rate is still low, so it is particularly important to explore appropriate conversion therapy options. This article mainly describes the existing conversion therapies, hoping to provide help and ideas for exploring the best conversion therapies in the future.